title: [Retrospective study of clinicopathological characteristics in bronchopulmonary carcinoid].
abstract: OBJECTIVE
  Bronchopulmonary carcinoid (BPC) account for less than 2% of all primary lung malignant tumors, but few related studies were reported. The aim of this study is to analyze this rare disease's clinicopathological characteristics.
  
  
  METHODS
  The clinical data of 28 patients with BPC in Cancer Center of Sun Yat-sen University, from January 1994 to June 2009, were enrolled into retrospective analysis. First, the corresponding paraffin blocks reexamined, slice up and stained, multiple pathologists re-consulted, and its subsets (typical carcinoid, TC; atypical carcinoid, AC) defined. Second, the clinical characteristics and immunohistochemical markers and its relationship with prognosis were analyzed.
  
  
  RESULTS
  First, the 5-year survival for overall and TC, AC was 56% and 70%, 41% respectively in 28 cases. The markers CD99, Bcl-2 and Ki-67 expression correlated significantly with the BPC subsets (P = 0.017, P = 0.043, and P = 0.033 respectively). Further univariate analysis revealed that advanced TNM staging (P = 0.037), lymph node metastasis (P = 0.001) and Ki-67 nucleolus's positive expression (P = 0.009) are poor prognostic factors. Second, the overall, TC, AC 5-year survival rate was 73%, 83%, 57% respectively in 20 cases underwent the radically surgical resection. Further univariate analysis revealed that AC subset (P = 0.013), lymph node metastasis (P = 0.004) and Ki-67 nucleolus's positive expression (P = 0.006), advanced TNM staging (P = 0.047) are poor prognostic factors in this 20 cases. Third, as univariate analysis, local recurrence and metastasis (n = 4) correlate significantly with Ki-67 nucleolus's and Bcl-2 positive expression (P = 0.027, 0.045, respectively).
  
  
  CONCLUSIONS
  The prognosis of BPC was better than other types of primary lung cancer. Ki-67, Bcl-2 high expression and advanced TNM staging are the poor recurrence and prognostic factors of BPC. The radical surgery remains the treatment of choice for resectable candidates in BPC as NSCLC.
authors.affiliation: State Key Laboratory of Oncology in South China, Department of Thoracic Surgery, Cancer Center of Sun Yat-sen University, Guangzhou 510060, China.
authors.forename: Hongliang
authors.initials: H
authors.lastname: Liao
authors.forename: Huilan
authors.initials: H
authors.lastname: Rao
authors.forename: Xu
authors.initials: X
authors.lastname: Zhang
authors.forename: Yongbin
authors.initials: Y
authors.lastname: Lin
authors.forename: Mingran
authors.initials: M
authors.lastname: Jie
authors.forename: Jianhua
authors.initials: J
authors.lastname: Fu
authors.forename: Hao
authors.initials: H
authors.lastname: Long
authors.forename: Tiehua
authors.initials: T
authors.lastname: Rong
authors.forename: Peng
authors.initials: P
authors.lastname: Lin
mesh_terms: D000328:Adult; D002276:Carcinoid Tumor / Q000401:mortality / Q000473:pathology* / Q000628:therapy; D004268:DNA-Binding Proteins / Q000032:analysis; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D019394:Ki-67 Antigen / Q000032:analysis; D008175:Lung Neoplasms / Q000401:mortality / Q000473:pathology* / Q000628:therapy; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000032:analysis; D012189:Retrospective Studies; D014157:Transcription Factors
chemical_list: D004268:DNA-Binding Proteins; D019394:Ki-67 Antigen; D019253:Proto-Oncogene Proteins c-bcl-2; C504003:TTF1 protein, human; D014157:Transcription Factors